Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

ApoGlyx

Apoglyx logo

 

The American Peter Agre won the Nobel Prize in 2003 for the discovery of aquaporins. Aquaporins are channels for water to enter and leave cells, with broad importance in health and disease, ranging from maintaining the body’s fluid balance to roles in cancer, diabetes, malaria, inflammation, autoimmunity and sepsis. Professor Per Kjellbom and his colleagues have identified how this water flow can be regulated. ApoGlyx develops first-in-class therapies based on aquaporin inhibitors.

ApoGlyx' most advanced approach is targeting sepsis, which is estimated to affect up to 50 million people every year and could be the cause of 11 million deaths, according to the Global Sepsis Alliance.

 

ApoGlyx website

 

 

 

ApoGlyx

Developing new therapeutic concepts for metabolic and inflammatory diseases, f.x. sepsis.

Founded by Per Kjellbom, Lund University, Søren Nielsen, Aalborg University and Michael Rützler, Aalborg University.

Portfolio company since 2008.

 

Portfolio Manager LU Holding:

christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78